Drug Interactions During Phototherapy: Medications That Affect Bilirubin Metabolism

Introduction: Drug Safety During Neonatal Phototherapy

Phototherapy is the most widely used treatment for neonatal jaundice, and neonates receiving phototherapy often require concurrent medications for infections, pain, respiratory support, and other conditions. Understanding the interactions between these medications and bilirubin metabolism is essential for safe and effective clinical practice. Drug interactions in the context of phototherapy can occur through three primary mechanisms: displacement of bilirubin from albumin binding sites, alteration of bilirubin metabolism pathways, and photosensitivity reactions under phototherapy light.

This guide provides Indian neonatologists with a comprehensive reference for identifying and managing drug interactions during phototherapy, with particular attention to medications commonly used in Indian NICU and community settings. Effective phototherapy using properly calibrated LED units, such as those available through HEAMAC phototherapy rental, forms the foundation of jaundice treatment within which drug safety must be carefully maintained.

Mechanism 1: Bilirubin Displacement from Albumin

Understanding Displacement Risk

Several commonly used neonatal medications bind to the same albumin sites as bilirubin. When these drugs displace bilirubin from albumin, they increase the free (unbound) bilirubin fraction, which is the neurotoxic form that can cross the blood-brain barrier. Even a small increase in free bilirubin can be dangerous in neonates approaching exchange transfusion thresholds.

High-Risk Displacement Drugs

Drug	Displacement Potency	Clinical Recommendation	Indian Context
Ceftriaxone	Very high	CONTRAINDICATED in jaundiced neonates	Common in Indian NICUs—must be avoided
Sulfonamides (cotrimoxazole)	Very high	CONTRAINDICATED in neonates	Still prescribed in some settings
Sulfisoxazole	Very high	CONTRAINDICATED in neonates	Rarely available in India
Furosemide	Moderate	Use with caution; monitor B/A ratio	Commonly used for fluid management
Ibuprofen	Moderate	Use with caution for PDA closure	Standard PDA treatment
Diazepam	Moderate	Avoid in jaundiced neonates if possible	Used for seizures—prefer phenobarbital

Ceftriaxone: The Most Critical Interaction

Ceftriaxone deserves special emphasis as it is the most clinically relevant bilirubin-displacing drug in Indian neonatal practice. Despite being contraindicated in neonates (especially hyperbilirubinemic and preterm), it continues to be prescribed in some Indian hospitals due to its broad spectrum and convenience. Key facts:

• Ceftriaxone displaces bilirubin from albumin in a dose-dependent manner
• In vitro studies show 30-40% increase in free bilirubin at therapeutic ceftriaxone concentrations
• The displacement effect is more pronounced in hypoalbuminemic and preterm neonates
• AAP, WHO, NNF, and IAP all contraindicate ceftriaxone in jaundiced neonates
• Alternative: Cefotaxime provides similar gram-negative coverage without significant bilirubin displacement

NNF Alert: Ceftriaxone must NEVER be used in neonates with hyperbilirubinemia. Cefotaxime is the recommended alternative third-generation cephalosporin. This is especially critical in Indian government hospitals where antibiotic selection protocols must be strictly enforced.

Mechanism 2: Drugs Affecting Bilirubin Metabolism

Drugs That Enhance Bilirubin Clearance

Drug	Mechanism	Clinical Use in Jaundice
Phenobarbital	UGT1A1 induction via CAR/PXR	Crigler-Najjar Type II; not for routine jaundice
Clofibrate	UGT1A1 induction via PPARα	Investigational adjunct to phototherapy
UDCA	Choleresis, bile flow enhancement	Cholestatic jaundice only

Drugs That Impair Bilirubin Clearance

• Chloramphenicol: Inhibits hepatic glucuronidation (competes with bilirubin for UGT1A1). Still used in some Indian government hospitals; avoid in jaundiced neonates
• Novobiocin: Potent UGT1A1 inhibitor; not commonly used but historically important
• Rifampicin: Initial enzyme inhibition (1-2 days) before induction effect; may transiently worsen jaundice
• HIV protease inhibitors: Atazanavir and indinavir inhibit UGT1A1; relevant in PMTCT settings

Drugs That Increase Bilirubin Production

• Oxytocin (maternal): High-dose oxytocin induction has been associated with neonatal hyperbilirubinemia, possibly through increased RBC fragility and hemolysis
• Oxidant drugs in G6PD deficiency: Primaquine, dapsone, naphthalene exposure causing hemolytic bilirubin surge
• Vitamin K (high dose): Pharmacological doses greater than 5 mg IV may rarely cause hemolysis; standard 1 mg IM prophylaxis is safe

Mechanism 3: Photosensitivity Reactions

Drugs Causing Photosensitivity Under Phototherapy Light

Some medications can cause enhanced skin sensitivity to the blue-green spectrum light used in phototherapy (420-490 nm wavelength). While phototherapy light is different from UV radiation, certain drug-induced photosensitivity reactions can still occur:

• Fluoroquinolones: Ciprofloxacin and levofloxacin can cause photosensitivity; not routinely used in neonates but relevant in rare cases
• Metalloporphyrins (tin mesoporphyrin): Cause transient erythema under phototherapy light (research setting only)
• Amiodarone: Blue-gray discoloration may be exacerbated by phototherapy light; rarely used in neonates

Phototherapy Effects on IV Medications

Drug Photodegradation

Phototherapy light can degrade certain medications administered through IV tubing exposed to the light source:

Medication	Photodegradation Risk	Precaution
Parenteral nutrition with lipids	High—lipid peroxidation	Shield IV bag and tubing with foil or amber covers
Multivitamin infusions	High—riboflavin degradation	Shield from light; use amber tubing
Sodium nitroprusside	High—photolysis to cyanide	Always shield from light (standard practice)
Furosemide	Moderate	Administer via syringe; avoid prolonged light exposure
Metronidazole	Moderate	Shield from direct phototherapy light

Practical Tip: In busy Indian NICUs where multiple infusions run simultaneously during phototherapy, use foil wrapping or amber-colored tubing covers for light-sensitive medications. This is especially important for TPN lipid infusions, which are at highest risk of photodegradation and peroxide formation under phototherapy light.

Fluid and Electrolyte Considerations

Increased Insensible Water Loss

Phototherapy increases insensible water losses by approximately 20-40% through enhanced transepidermal evaporation. This has implications for concurrent drug therapy:

• Aminoglycosides: Volume expansion from increased fluids may lower gentamicin/amikacin trough levels; monitor levels and adjust doses accordingly
• Vancomycin: Altered volume of distribution may require dosing adjustment
• Caffeine citrate: Increased fluid intake may dilute levels; monitor for apnea recurrence
• Electrolyte supplementation: Increased fluid losses may necessitate additional sodium and potassium supplementation

Safe Drug Prescribing During Phototherapy: Quick Reference

Category	Safe Choices	Avoid/Use Caution
First-line antibiotics	Ampicillin + Gentamicin	Ceftriaxone, Sulfonamides, Chloramphenicol
Cephalosporins	Cefotaxime, Cefazolin	Ceftriaxone (contraindicated)
Analgesics	Paracetamol, Fentanyl	High-dose ibuprofen (displacement)
Anticonvulsants	Phenobarbital (may benefit jaundice)	Diazepam (displacement)
Diuretics	Spironolactone	Furosemide (moderate displacement, use with caution)
PDA closure	Ibuprofen (with B/A monitoring)	Indomethacin (similar displacement risk)

Practical Protocol for Indian NICUs

1. Review all concurrent medications when initiating phototherapy
2. Substitute ceftriaxone with cefotaxime in any neonate with jaundice
3. Avoid sulfonamides in all neonates during the jaundice-risk period
4. Shield light-sensitive IV infusions (TPN, multivitamins) from phototherapy light
5. Increase fluid intake by 10-20 mL/kg/day during phototherapy
6. Monitor aminoglycoside levels if phototherapy duration exceeds 48 hours
7. Calculate B/A ratio when using drugs with moderate displacement potential (furosemide, ibuprofen)
8. Ensure phototherapy devices are properly calibrated for optimal irradiance—HEAMAC LED phototherapy units maintain consistent spectral output for reliable treatment

Conclusion

Drug safety during phototherapy requires awareness of three interaction mechanisms: albumin displacement, metabolism alteration, and photosensitivity. The single most important intervention is avoiding ceftriaxone in jaundiced neonates—a practice that remains inadequately enforced in some Indian healthcare settings. By maintaining a systematic approach to medication review and using effective phototherapy equipment, clinicians can maximize jaundice treatment efficacy while minimizing drug-related complications.